tirzepatide medullary thyroid cancer Mixed and Papillary Carcinoma in a Patient on Medullary Thyroid Cancer | UCSF

Each synthesis batch includes a rigorous Certificate of Analysis (CoA) ensuring strict lot/batch traceability

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity

Managing weight loss while taking levothyroxine for thyroid health requires careful coordination

This Phase 1 trial, completed on an accelerated timeline, marks a key milestone in validating both the safety and translational potential of Hanmis next generation triple agonist in humans.Based on these results, Hanmi plans to initiate Phase 2 clinical trials in the second half of 2025, evaluating the long-term effects of HM15275 in reducing body weight and preserving lean mass in patients with severe obesity

Same manufacturing process

Conclusions Both formulations of semaglutide provided clinically and statistically significant reductions in HbA1c and weight in real-world practice